Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 4/2010

01-11-2010 | Letter to the Editor

Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience

Authors: Junya Kuroda, Tsutomu Kobayashi, Yasuhiko Tsutsumi, Mio Yamamoto, Muneo Ohshiro, Nana Sasaki, Yuji Shimura, Shinsuke Mizutani, Hisao Nagoshi, Miki Kiyota, Ryuko Nakayama, Hitoji Uchiyama, Yosuke Matsumoto, Shigeo Horiike, Chihiro Shimazaki, Masafumi Taniwaki

Published in: International Journal of Hematology | Issue 4/2010

Login to get access

Excerpt

Allogeneic hematopoietic stem cell transplantation (allo-SCT) can result in remission and long-term survival for multiple myeloma (MM), but its effect has been often hampered by high rates of therapy-related death by graft-versus-host diseases (GVHD), disease progression, or infection [1]. We retrospectively investigated the efficacy and safety of Bortezomib (Bor) alone or with dexamethasone (Dex) (BD) for MM patients with disease progression following allo-SCT. …
Appendix
Available only for authorised users
Literature
1.
Bensinger WI. Role of autologous and allogeneic stem cell transplantation in myeloma. Leukemia. 2009;23:442–8.CrossRefPubMed
2.
van de Donk NW, Kröger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H, et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood. 2006;107:3415–6.
3.
Mateos-Mazon J, Pérez-Simón JA, Lopez O, Hernández E, Etxebarria J, San Miguel JF. Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation. Haematologica. 2007;92:1295–6.CrossRefPubMed
4.
El-Cheikh J, Michallet M, Nagler A, de Lavallade H, Nicolini FE, Shimoni A, et al. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. Haematologica. 2008;93:455–8.CrossRefPubMed
5.
Bruno B, Patriarca F, Sorasio R, Mattei D, Montefusco V, Peccatori J, et al. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. Haematologica. 2006;91:837–9.PubMed
6.
Sun K, Welniak LA, Panoskaltsis-Mortari A, O’Shaughnessy MJ, Liu H, Barao I, et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA. 2004;101:8120–5.CrossRefPubMed
7.
Sun K, Wilkins DE, Anver MR, Sayers TJ, Panoskaltsis-Mortari A, Blazar BR, et al. Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood. 2005;106:3293–9.CrossRefPubMed
8.
Minnema MC, van der Veer MS, Aarts T, Emmelot M, Mutis T, Lokhorst HM. Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+ Foxp3+ T cells. Leukemia. 2009;23:605–7.CrossRefPubMed
Metadata
Title
Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience
Authors
Junya Kuroda
Tsutomu Kobayashi
Yasuhiko Tsutsumi
Mio Yamamoto
Muneo Ohshiro
Nana Sasaki
Yuji Shimura
Shinsuke Mizutani
Hisao Nagoshi
Miki Kiyota
Ryuko Nakayama
Hitoji Uchiyama
Yosuke Matsumoto
Shigeo Horiike
Chihiro Shimazaki
Masafumi Taniwaki
Publication date
01-11-2010
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 4/2010
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-010-0709-3

Other articles of this Issue 4/2010

International Journal of Hematology 4/2010 Go to the issue

Case Report

Aggressive sporadic histiocytic sarcoma with immunoglobulin heavy chain gene rearrangement and t(14;18)

Case Report

Incidental carcinomas detected by PET/CT scans in patients with malignant lymphoma

Case Report

Histiocytic sarcoma with two immunohistopathologically distinct populations

Original Article

Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: the collaborative study at six institutes in Kyoto and Osaka

Case Report

Successful salvage treatment of blastic natural killer cell lymphoma with methotrexate

Case Report

Expanded distribution of the T315I mutation among hematopoietic stem cells and progenitors in a chronic myeloid leukemia patient during imatinib treatment
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits